Compare prices and buy Semaglutide from 32 research peptide vendors - also called suppliers or sources. Updated daily.
A GLP-1 receptor agonist built on the 31-residue GLP-1(7-37) chain (CAS 910463-68-2, C187H291N45O59). In GLP-1 numbering, aminoisobutyric acid at position 8 resists DPP-4 cleavage, arginine replaces lysine 34, and lysine 26 carries a linker and C18 fatty diacid that binds albumin, giving a half-life of about one week. FDA-approved by Novo Nordisk as Ozempic (injection and tablets) and Rybelsus for type 2 diabetes and Wegovy (injection and tablets) for weight management, with added cardiovascular, kidney and liver indications.
For research purposes only. Not medical advice.
Semaglutide (Novo Nordisk, C187H291N45O59) is an analog of GLP-1(7-37), a 31-residue active form of the gut hormone glucagon-like peptide-1. Positions here use the label's native GLP-1 numbering, which starts at 7, so position 8 is the chain's second residue. The FDA label and Novo Nordisk's 2015 discovery paper (Journal of Medicinal Chemistry) describe three changes:
The label credits albumin binding, which slows renal clearance and metabolic degradation, for the half-life of about one week. The design descends from Novo Nordisk's liraglutide, which shares the Arg34 backbone but carries palmitic acid on a shorter linker. Against liraglutide, the discovery paper reports higher albumin affinity and roughly threefold lower GLP-1 receptor affinity.
Novo Nordisk sponsored each trial below, and each was published in The New England Journal of Medicine.
SELECT participants on semaglutide stopped treatment for adverse events more often (16.6% versus 8.2%). SUSTAIN-6 (2016) and SOUL (2025) underpin the cardiovascular indications for Ozempic and Rybelsus. The tirzepatide page covers the head-to-head SURMOUNT-5 trial, and the three-way comparison explains why trials run separately cannot rank these compounds.
As of October 2026, semaglutide is the active ingredient in five FDA-approved products under three Novo Nordisk brands.
Those approvals, rather than the FDA bulk-substance nomination lists that govern older research peptides, set semaglutide's regulatory status. WADA monitors it but does not prohibit it in sport.
The FDA listed semaglutide injection products in shortage from 2022 until February 21, 2025. Its enforcement discretion for compounding that depended on the shortage listing ended in April 2025 for state-licensed pharmacies (503A) and on May 22, 2025 for outsourcing facilities (503B). The agency says the salt forms semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs, and it has warned companies that sold semaglutide falsely labeled "for research purposes" directly to consumers with dosing instructions.
On the generic-drug track, the FDA's product-specific guidance for semaglutide injection, revised in July 2026, covers recombinant, synthetic and semi-synthetic versions (Novo Nordisk makes its peptide backbone by yeast fermentation). On April 7, 2026, the FDA tentatively approved a generic semaglutide injection from Apotex, a status that does not permit marketing until patent or exclusivity issues are resolved.
Many vendors use a generational "GLP-N" code, in which GLP1 means semaglutide, GLP2 tirzepatide and GLP3 retatrutide. Our post on what GLP-3 means covers the whole code series. A bare "GLP-1" in a vendor title typically means semaglutide, and suffixes such as S, SM and SG mark it within a code family (GLP1-S, GLP-1 SM, PG-1SG). PeptideScouter verifies each listing against its published CAS number (910463-68-2) or molecular formula before mapping it. Blends with the amylin analog cagrilintide, the pairing in Novo Nordisk's CagriSema, appear on the semaglutide + cagrilintide page.
PeptideScouter computes a per-milligram price only for vials, so tablet listings show their package price here but stay out of per-milligram comparisons. A research-grade tablet is not Rybelsus, Ozempic tablets or Wegovy tablets, which rely on the absorption enhancer SNAC. The orforglipron page covers why oral peptides need one and a small molecule does not.
Not as a product. Ozempic, Rybelsus and Wegovy are FDA-approved Novo Nordisk medicines that contain semaglutide, and each approval covers that specific product and its labeled uses. Research-grade semaglutide sold by peptide vendors is a separate material that the FDA has not approved, offered for laboratory research only and not for human consumption. The FDA has warned companies that sold semaglutide falsely labeled for research purposes directly to consumers with dosing instructions, and it states that the salt forms semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs.
The FDA declared the national shortage of semaglutide injection products, which began in 2022, resolved on February 21, 2025. The enforcement discretion it had extended to compounding that depended on the shortage listing ended in April 2025 for state-licensed pharmacies under section 503A and on May 22, 2025 for outsourcing facilities under section 503B. In an April 2026 update the FDA stated that semaglutide appears on neither the 503B bulks list nor the drug shortage list, and reminded pharmacies that one condition of the 503A exemption is not compounding, regularly or in inordinate amounts, essentially copies of a commercially available drug. The FDA also says it is aware of no lawful basis for compounding with the salt forms semaglutide sodium or semaglutide acetate.
Semaglutide activates one receptor, GLP-1. Tirzepatide, approved as Mounjaro and Zepbound, activates the GIP and GLP-1 receptors, and retatrutide, which is investigational, adds the glucagon receptor to those two. The molecules are also built differently. Semaglutide is a modified GLP-1 sequence carrying a C18 fatty diacid, while tirzepatide is based on the GIP sequence and carries a C20 fatty diacid. In both, the fatty acid binds albumin and extends the half-life.
Many research vendors use a generational code in which GLP1 means semaglutide, GLP2 means tirzepatide and GLP3 means retatrutide. The numbers follow drug generations and are not a scientific classification. GLP-1 is the gut hormone semaglutide mimics, while GLP-2 is a different hormone whose approved analog is teduglutide, so a GLP2 label in this convention does not mean a GLP-2 drug. Letter suffixes such as S, SM or SG identify semaglutide within a vendor's code family. PeptideScouter maps a listing to semaglutide only after checking its published CAS number or molecular formula.
No. Semaglutide is on the World Anti-Doping Agency's Monitoring Program, which covers substances that are not on the Prohibited List but that WADA tracks to detect patterns of misuse in sport. The 2026 program listed markers of semaglutide and tirzepatide, and the 2027 program lists both under the heading GLP-1 agonists, in and out of competition.
Semaglutide is sold by 32 research peptide vendors indexed on PeptideScouter, with 88 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
30 of the 32 indexed vendors currently have Semaglutide in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Renova Peptides currently lists Semaglutide at $1.33/mg, the lowest listed price across 32 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.20/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 32 vendors listing Semaglutide publish a PeptideScouter code, worth 10% to 50% off. Applied, the lowest effective price falls from $1.33/mg listed to $1.20/mg at Renova Peptides. Each vendor's code is shown beside its price in the table above.
Semaglutide ranges from $1.33/mg to $15.80/mg across 88 listings from 32 research peptide vendors, normalized to USD per milligram and refreshed daily.
32 research peptide vendors currently list Semaglutide on PeptideScouter, with 30 in stock right now. We track 88 listings across size and kit variants.
Semaglutide's CAS Registry Number is 910463-68-2. It is also sold as S-GLP1, GLA-1 SM, GLP1-Sema.
